Literature DB >> 7916003

Chromosomal localization, genomic structure, and allelic polymorphism of the human CD79 alpha (Ig-alpha/mb-1) gene.

S Hashimoto1, H W Mohrenweiser, P K Gregersen, N Chiorazzi.   

Abstract

The germline DNA sequence of the human CD79 alpha (Ig-alpha/mb-1) gene was determined by polymerase chain reaction sequencing of a cosmid clone derived from an arrayed human chromosome 19 library. The CD79 alpha gene was localized to chromosome 19q13.2; this localization places the gene within the CEA-like gene cluster with the following gene order: -CEA-CGM1-CD79 alpha-RPS11-ATP1A3-BGP-CGM9-. The genomic organization of the human CD79 alpha gene resembles the mouse counterpart with five exons interrupted by four introns. Computer analyses suggest the presence of transcription regulatory elements known to be important in the regulation of mouse CD79 alpha (AP-1, EBF, AP-2, MUF2, and SP-1 sites), as well as elements not found in the mouse gene (an NK-kappa B binding site and a series of E-box motifs). Similar to the mouse gene, the 5' flanking region of human CD79 alpha lacks a TATA box; however, unlike mouse CD79 alpha, a classical octamer motif could not be identified in the human gene. Finally, a new Rsa I restriction fragment length polymorphism was defined in the non-coding regions of the human gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916003     DOI: 10.1007/bf00189974

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  58 in total

1.  BLyF, a novel cell-type- and stage-specific regulator of the B-lymphocyte gene mb-1.

Authors:  A L Feldhaus; D Mbangkollo; K L Arvin; C A Klug; H Singh
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

Review 2.  NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control.

Authors:  M J Lenardo; D Baltimore
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

3.  Heterogeneously initiated transcription from the pre-B- and B-cell-specific mb-1 promoter: analysis of the requirement for upstream factor-binding sites and initiation site sequences.

Authors:  A Travis; J Hagman; R Grosschedl
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

Review 4.  Immunoglobulin gene transcription.

Authors:  L M Staudt; M J Lenardo
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

5.  Human mb-1 gene: complete cDNA sequence and its expression in B cells bearing membrane Ig of various isotypes.

Authors:  L M Yu; T W Chang
Journal:  J Immunol       Date:  1992-01-15       Impact factor: 5.422

6.  Identification of a transcriptional unit adjacent to the breakpoint in the 14;19 translocation of chronic lymphocytic leukemia.

Authors:  T W McKeithan; H Ohno; M O Diaz
Journal:  Genes Chromosomes Cancer       Date:  1990-01       Impact factor: 5.006

Review 7.  Function and activation of NF-kappa B in the immune system.

Authors:  P A Baeuerle; T Henkel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

8.  Structure of the 5' ends of immunoglobulin genes: a novel conserved sequence.

Authors:  T G Parslow; D L Blair; W J Murphy; D K Granner
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

9.  Cloning and functional characterization of early B-cell factor, a regulator of lymphocyte-specific gene expression.

Authors:  J Hagman; C Belanger; A Travis; C W Turck; R Grosschedl
Journal:  Genes Dev       Date:  1993-05       Impact factor: 11.361

10.  Three B-cell surface molecules associating with membrane immunoglobulin.

Authors:  R M Parkhouse
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

View more
  2 in total

Review 1.  Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.

Authors:  Michael Y Choi; Thomas J Kipps
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

2.  Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a).

Authors:  Melinda S Gordon; Cindy M Kanegai; Jeanette R Doerr; Randolph Wall
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-21       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.